Skip to main content

Table 1 Baseline information

From: Continuous glucose monitoring for detection of glycemic variability, hypoglycemia, and hyperglycemia in women with eating disorders

  

All patients

ANR

ANBP

BN

P

Multiple comparison

Number

 

18

4

9

5

  

Age

year

31(26,37)

26(22,32)

31(29,33)

35(32,41)

0.298

 

Disease duration

year

13.5 ± 12.4

4.5 ± 3.8

16.1 ± 14.3

16.8 ± 10.9

0.233

 

Height

cm

158.9(155.0,162.2)

155.3(150.9,160.6)

157.4(155.2,160.0)

162.2(159.5,166.1)

0.290

 

Weight

kg

42.3 ± 8.5

34.3 ± 5.8

40.1 ± 4.8

52.6 ± 5.1

 < 0.001

vsP < 0.001, vsP = 0.001

BMI

kg/m2

16.6 ± 2.6

14.1 ± 1.6

15.9 ± 1.8

19.9 ± 0.9

 < 0.001

vsP < 0.001, vsP = 0.001

The frequency of binge eating

times/28 days

-

0.0 ± 0.0

27.7 ± 21.1

6.4 ± 10.5

0.021

vsP = 0.033

The frequency of vomiting

times/28 days

-

0.0 ± 0.0

31.0 ± 22.8

1.0 ± 1.0

0.006

vsP = 0.019, vsP = 0.015

The frequency of laxative abuse

times/28 days

-

0.0 ± 0.0

15.6 ± 24.6

9.0 ± 12.6

0.414

 

The frequency of compulsive exercise

times/28 days

-

0.5 ± 1.0

3.4 ± 9.3

11.6 ± 13.8

0.224

 

Plasma blood glucose

mg/dl

80.2 ± 10.6

79.0 ± 6.5

79.4 ± 13.6

83.0 ± 6.8

0.828

 

Serum inslin

μU/ml

2.5(1.6,3.3)

2.8(1.6,4.1)

2.5(1.2,2.9)

2.4(2.3,3.9)

0.724

 

HOMA-IR

 

0.52(0.25,0.69)

0.53(0.29,0.84)

0.52(0.22,0.66)

0.52(0.47,0.82)

0.674

 

HOMA-β

 

43.2(29.7,82.8)

71.7(47.0,78.5)

41.5(27.2,90.0)

43.6(34.6,63.8)

0.840

 

HbA1c

%

5.1 ± 0.2

5.3 ± 0.3

5.0 ± 0.2

5.2 ± 0.2

0.185

 
  1. Presented by mean ± SD or median (Q1,Q3) depending on the normality based on the Shapiro–Wilk test
  2. P value was based on either One-way ANOVA or Kruskal–Wallis test depending on the normality based on the Shapiro–Wilk test
  3. The multiple comparisons shown in the table are based on Tukey's HSD test
  4. Abbreviations: ED Eating disorder, ANR Anorexia nervosa restricting, ANBP Anorexia nervosa binge eating/purging, BN Bulimia nervosa, HOMA-IR Homeostasis model assessment-insulin resistance, HOMA-β Homeostasis model assessment-beta cell